Identification of the genetic basis of systemic lupus erythematosus (SLE) may contribute to the discovery of effective drugs before renal involvement. Our aim of this study was to estimate the association between Fc gamma receptor (FcγR) polymorphisms and SLE and renal involvement in Egyptian patients. FcγRIIB and FcγRIIA R131H gene polymorphisms were genotyped in 180 Egyptian adults. Genotyping for FcγRIIA R131H was performed using allele-specific PCR and FcγRIIB-Ile232 Thr polymorphism was genotyped using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). The study showed that the homozygous genotype (Thr/Thr) of FcγRIIB significantly increased in all SLE patients (90 patients) and in SLE patients complicated with nephritis (61 patients). The Thr allele was significantly associated with an increased risk of the disease in all the patients and in patients complicated with nephritis. Our study demonstrated an association of FcγRIIB polymorphisms with SLE and lupus nephritis and a lack of association of FcγRIIA polymorphisms with SLE in the Egyptian patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11033-013-2912-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization and structural analysis of a leucine aminopeptidase using site-directed mutagenesis.
AMB Express
December 2024
College of Life Science, South-Central Minzu University, Wuhan, 430074, China.
Amp0279 (EC 3.4.11.
View Article and Find Full Text PDFAssociation between functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases: a meta-analysis.
Pharmacogenomics J
November 2023
Department of Rheumatology, Korea University Medicine, Seoul, Korea.
Objectives: To investigate the association between the functional Fc gamma receptor 3 A (FCGR3A) V158F and FCGR2A R131H polymorphisms and rituximab therapy in patients with autoimmune diseases.
Methods: We searched the Medline, Embase, and Cochrane databases for relevant articles. We conducted a meta-analysis of the association between FCGR3A V158F and FCGR2A R131H polymorphisms and responsiveness to rituximab in patients with autoimmune diseases.
Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis.
Int J Rheum Dis
July 2023
Department of Rheumatology, Korea University Medicine, Seoul, South Korea.
Objectives: This study aimed to investigate the association between functional Fc gamma receptor 3A (FCGR3A) V158F and FCGR2A R131H polymorphisms and biologic therapy in rheumatoid arthritis (RA) patients.
Methods: We searched Medline, Embase, and Cochran databases for available articles. This study is a meta-analysis of the association between the FCGR3A V158F and FCGR2A R131H polymorphisms and their responsiveness to biologics in RA patients.
Impact of FCGR2A R131H, FCGR3A F158V and FCGR3B NA1/NA2 polymorphisms on response to Fc-containing TNF inhibitors in Tunisian rheumatoid arthritis patients.
Drug Metab Pers Ther
June 2023
Laboratory of Research in Immunology, Renal Transplantation and Immunopathology (LR03SP01), Charles Nicolle Hospital of Tunis, Tunis El Manar University, Tunis, Tunisia.
Article Synopsis
- The study investigates how single nucleotide polymorphisms (SNPs) of Fc-gamma receptors (FcgRs) may affect the response to TNF-inhibitors (TNFi) in rheumatoid arthritis (RA) patients in Tunisia.
- Researchers analyzed 47 RA patients over six months, focusing on the effectiveness of TNFi treatments like etanercept, adalimumab, and infliximab while genotyping specific SNPs.
- Results indicated that low-affinity FcgRs were linked to better treatment outcomes, while high-affinity variants were associated with poorer responses, highlighting the potential role of these genetic markers in personalizing RA treatment.
Assessment of the influence of Fc-γ receptor polymorphisms on biologics' pharmacokinetics in Tunisian rheumatoid arthritis patients.
Br J Clin Pharmacol
June 2023
Laboratory of Research in Immunology, Renal Transplantation and Immunopathology (LR03SP01), Charles Nicolle Hospital, Tunis El Manar University, Tunis, Tunisia.
Article Synopsis
- The study investigates whether variations in Fc-γ receptors caused by specific genetic changes (single nucleotide polymorphisms) affect how well therapeutic monoclonal antibodies are cleared from the body and influence the development of anti-drug antibodies.
- Conducted on Tunisian rheumatoid arthritis patients treated with various biologic drugs, the study measured serum drug levels and the presence of anti-drug antibodies while genotyping patients for specific Fc-γ receptor variations.
- Results indicate that while most patients had serum drug levels within the therapeutic range, a minority developed anti-drug antibodies, with a notable association between the high affinity FcgR2A R131H receptor and antibody development, prompting recommendations for further research with larger sample sizes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!